A new type of treatment allows for a significant improvement in the survival rate of women under the age of 60, who suffer the most common type of cancer, researchers in Chicago say.
These scientists, who presented the results of a global clinical trial, showed that the addition of a riboseclip inhibitor to the cell cycle to treatment allowed the survival rate to be increased to 70 percent after three and a half years.
The death rate of patients receiving this treatment was 29 percent lower than those who received placebo, according to the results presented at the annual conference of the Society of Clinical Oncology (ASCO), which gathers international experts on cancer over the weekend.
The study focused on patients with breast cancer that interact with some hormones and form two-thirds of the infections in women before menopause, according to the main stomach of the study Sarah Horvitz.
In this case, patients usually receive treatments designed to stop the screening of estrogen hormones.
The new treatment works by influencing enzymes that play the role of motor and disrupt the cell cycle.
"A better response can be achieved, or even cancer eliminated by adding these inhibitors to the cell cycle," Horvitz said.
This treatment is less toxic than conventional chemotherapy because it specifically targets cancer cells and prevents them from multiplying.
The clinical trial was based on more than 670 cases involving only women under the age of 59 who were at an advanced stage of the disease (stage IV) without previously receiving hormone therapy.
"It's about women who have been diagnosed with advanced disease because we do not have monitoring protocols for the disease that are better for younger women," Horvitz said.
"It's an important study," said Harold Bornstein, an oncologist who did not participate in the research because it shows that cell cycle control "reflects a marked improvement" in survival.
Harold Bornstein works at the Dana-Farber Foundation Institute in Boston.
The treatment is given in the form of pills for 21 days followed by a seven-day stop to make the rebound recuperate as two-thirds of the patients suffered a moderate or severe decline in the level of leukocytes.
A 28-day treatment costs $12,553, said Jamie Bennett, spokeswoman for Novartis, which markets the treatment under the name of Kiskali, which also funded the study.
"Most patients with private insurance will not pay anything in the United States," she said.
About 268,000 good cases are expected to be registered in the United States in 2019, with a total population of 320 million. The advanced type of the disease is the leading cause of cancer deaths among women between the ages of 20 and 59.
The advanced stage of breast cancer is less prevalent in women before menopause, but it was up 2 percent between 1978 and 2008 among Americans between the ages of 20 and 39, according to a previous study. (AFP)